Edith A. Perez
#71,859
Most Influential Person Now
Puerto Rican hematologist-oncologist
Edith A. Perez's AcademicInfluence.com Rankings
Edith A. Perezmedical Degrees
Medical
#773
World Rank
#1015
Historical Rank
#276
USA Rank
Hematology
#14
World Rank
#15
Historical Rank
#7
USA Rank
Oncology
#44
World Rank
#47
Historical Rank
#15
USA Rank
Download Badge
Medical
Why Is Edith A. Perez Influential?
(Suggest an Edit or Addition)According to Wikipedia, Edith A. Pérez is a Puerto Rican hematologist-oncologist. She is the Serene M. and Frances C. Durling Professor of Medicine at the Mayo Clinic Alix School of Medicine. Early life and education Perez was born and raised in Humacao, Puerto Rico. Her mother was a teacher and librarian and her father owned a grocery store. During her freshman year at University of Puerto Rico, Río Piedras Campus, Perez's grandmother died. Her death motivated her to become a physician. In 1975, she graduated magna cum laude with a B.S. in Biology.
Edith A. Perez's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) (5306)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006) (3857)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2014) (3308)
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (2007) (2993)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013) (1551)
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. (2003) (1462)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2007) (1419)
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. (2015) (1097)
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer (2003) (1091)
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) (1044)
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014) (1004)
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. (2011) (961)
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) (880)
- Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. (2005) (769)
- Treatment of HER2-positive breast cancer: current status and future perspectives (2012) (767)
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014) (741)
- Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (2011) (685)
- Weekly paclitaxel in the adjuvant treatment of breast cancer. (2008) (673)
- Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. (1999) (652)
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
- The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen (2006) (577)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. (2008) (507)
- Phase III evaluation of fluoxetine for treatment of hot flashes. (2002) (479)
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast (2013) (476)
- Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance (2009) (427)
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. (2006) (418)
- Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. (2002) (392)
- Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. (2007) (388)
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. (2014) (379)
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer (2006) (361)
- Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. (2008) (357)
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane (2015) (347)
- Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. (2013) (346)
- HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. (2006) (344)
- Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. (2008) (326)
- Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. (2014) (324)
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. (2016) (317)
- Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. (2007) (314)
- Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. (2010) (305)
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (2016) (305)
- RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2011) (302)
- Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. (2006) (293)
- Clinical cardiac tolerability of trastuzumab. (2004) (276)
- ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. (1999) (271)
- Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. (1998) (266)
- Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. (2001) (262)
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. (2011) (251)
- Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (2007) (232)
- Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. (2008) (230)
- Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. (2015) (223)
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. (2010) (222)
- Adjuvant chemotherapy in older women with early-stage breast cancer. (2009) (220)
- Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. (2006) (215)
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. (2016) (212)
- HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. (2002) (211)
- Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. (2013) (211)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. (2009) (205)
- MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. (2011) (199)
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer (2012) (197)
- Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. (2015) (180)
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. (2008) (179)
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. (2016) (178)
- A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen (2006) (175)
- Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. (2009) (175)
- The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). (2005) (174)
- Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. (2008) (171)
- Final 5‐year results of Z‐FAST trial (2012) (171)
- 3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer (2009) (166)
- Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. (2012) (166)
- RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). (2009) (162)
- Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. (2009) (157)
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). (2015) (156)
- Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. (1993) (156)
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. (2015) (155)
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. (2006) (147)
- Integrated Analysis of Gene Expression, CpG Island Methylation, and Gene Copy Number in Breast Cancer Cells by Deep Sequencing (2011) (142)
- Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. (2006) (142)
- Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. (2014) (141)
- Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. (2010) (137)
- Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. (1999) (136)
- Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. (1998) (136)
- Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) (135)
- A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100 (2006) (135)
- Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. (2007) (131)
- HER2 testing: current status and future directions. (2014) (131)
- Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. (2016) (129)
- Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. (2005) (126)
- Pilot evaluation of gabapentin for treating hot flashes. (2002) (124)
- Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. (2011) (122)
- Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. (2003) (121)
- Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. (2005) (113)
- A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). (2010) (113)
- Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. (2010) (112)
- A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines (2011) (112)
- Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. (2004) (112)
- Renal salt wasting in patients treated with cisplatin. (1988) (111)
- Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer (2007) (111)
- Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. (2013) (111)
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
- Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). (2007) (103)
- Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity (2015) (103)
- Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. (2009) (99)
- p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression (2008) (99)
- Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. (2015) (97)
- Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. (2005) (97)
- Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. (2015) (94)
- Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors (2015) (93)
- Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. (2004) (93)
- Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial (2006) (92)
- Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer (2009) (92)
- Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer. (2012) (92)
- Treatment options for breast cancer resistant to anthracycline and taxane. (2009) (92)
- Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. (2012) (88)
- Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. (2012) (86)
- Phase II trial of dolastatin-10 in patients with advanced breast cancer (2005) (86)
- Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. (2006) (86)
- Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. (2009) (85)
- Cardiac toxicity of ErbB2-targeted therapies: what do we know? (2008) (84)
- Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. (2012) (83)
- A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma (2000) (83)
- Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. (2008) (79)
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. (2009) (79)
- Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC (2009) (78)
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) (2013) (77)
- Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer (2010) (77)
- Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (2014) (76)
- Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. (2012) (75)
- CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). (2012) (75)
- Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. (1991) (74)
- Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis (2013) (74)
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) (2016) (73)
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (73)
- Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. (2010) (73)
- SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer (2016) (72)
- Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study (2012) (71)
- E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer (2005) (71)
- Metastasectomy and Surgical Resection of the Primary Tumor in Patients With Stage IV Breast Cancer (2010) (71)
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. (2015) (70)
- Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer (2012) (69)
- Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. (2011) (69)
- Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. (1989) (68)
- Carboplatin in combination therapy for metastatic breast cancer. (2004) (67)
- Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. (1999) (66)
- Treatment options for patients with triple-negative breast cancer (2010) (66)
- Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. (2008) (66)
- Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). (2008) (65)
- Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. (2013) (65)
- The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up. (2009) (63)
- C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. (2011) (63)
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. (2008) (63)
- Current management of metastatic breast cancer. (1999) (62)
- Aromatase inhibitors and bone loss. (2006) (61)
- Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. (2009) (61)
- Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. (1990) (61)
- 5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) (2011) (61)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer (2008) (60)
- Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results (2016) (59)
- A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. (2007) (59)
- Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study (2014) (59)
- Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. (1995) (58)
- Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial (2005) (58)
- Recommendations for the use of antiemetics (1999) (57)
- Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results (2015) (56)
- Adjuvant therapy of triple negative breast cancer (2010) (56)
- Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? (2008) (56)
- Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437 (2011) (55)
- Current and emerging targeted therapies for metastatic breast cancer (2012) (55)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Gene Expression, Single Nucleotide Variant and Fusion Transcript Discovery in Archival Material from Breast Tumors (2013) (54)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (54)
- Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy (1998) (54)
- Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers (2012) (53)
- Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. (2005) (53)
- Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. (2009) (53)
- Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. (2010) (52)
- Improving patient care through molecular diagnostics. (2004) (52)
- The role of mammography in male patients with breast symptoms. (2007) (51)
- Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52 (2006) (50)
- Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE (2019) (50)
- Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial (2014) (49)
- Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. (2016) (49)
- Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations (2012) (49)
- International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (49)
- Future options with trastuzumab for primary systemic and adjuvant therapy. (2004) (48)
- Advances in adjuvant therapy for breast cancer. (2006) (48)
- Breast cancer management: opportunities and barriers to an individualized approach. (2011) (48)
- Quality of life after breast cancer surgery: What have we learned and where should we go next? (2009) (48)
- A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial (2010) (48)
- MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). (2011) (48)
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial (2013) (47)
- Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial (2015) (47)
- Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. (2006) (47)
- Prevention and treatment of osteoporosis in women with breast cancer. (2000) (46)
- Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (2012) (46)
- Effective Targeting of Estrogen Receptor–Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101 (2015) (46)
- Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. (2010) (45)
- 5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) (2009) (45)
- Treatment of metastatic breast cancer: looking towards the future (2009) (45)
- Molecularly targeted therapies for breast cancer. (2005) (45)
- Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review (2011) (45)
- Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. (1993) (45)
- Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. (2010) (44)
- TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. (2013) (44)
- Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. (2019) (44)
- Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 (2013) (44)
- Phase II Study of Gemcitabine Plus Cisplatin in Patients With Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial (2005) (43)
- Effect of body mass index on tumor characteristics and disease‐free survival in patients from the HER2‐positive adjuvant trastuzumab trial N9831 (2013) (43)
- Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104) (2008) (43)
- Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial (2017) (42)
- Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer (2014) (42)
- The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes (2017) (42)
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. (2019) (42)
- The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. (1992) (41)
- Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. (2009) (41)
- Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831 (2014) (41)
- Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. (2010) (40)
- Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. (2006) (40)
- N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. (2016) (40)
- Advances in screening, diagnosis, and treatment of breast cancer. (2004) (39)
- Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199 (2007) (38)
- Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. (2019) (38)
- Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. (2010) (37)
- Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population. (2009) (37)
- Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole (2015) (37)
- Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. (2010) (36)
- Phase I Trial of High-Dose Tamoxifen in Combination with Cisplatin in Patients with Lung Cancer and Other Advanced Malignancies (2003) (36)
- North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. (2010) (36)
- A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. (2002) (36)
- Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (2017) (35)
- Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. (1998) (35)
- HER2-Positive Breast Cancer: Current Treatment Strategies (2008) (35)
- Role of axillary node dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience. (2001) (35)
- Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials (2012) (34)
- Doxorubicin and Paclitaxel in the Treatment of Advanced Breast Cancer: Efficacy and Cardiac Considerations (2001) (34)
- Interleukin-2, Cisplatin, and 5-Fluorouracil for Patients with Non-Small Cell Lung and Head/Neck Carcinomas (1991) (34)
- Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries (2015) (33)
- Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. (2002) (33)
- Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer* (2002) (33)
- “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy (2015) (33)
- Evaluation of cisplatin dose intensity: current status and future prospects. (1989) (32)
- Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas (2004) (32)
- Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. (2015) (32)
- Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. (2009) (32)
- Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. (2016) (31)
- New drug development (2012) (31)
- Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. (2005) (31)
- 5‐year follow‐up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial (2015) (31)
- Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. (2016) (31)
- Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (30)
- Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines (1998) (30)
- Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy‐induced anemia (2007) (30)
- Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. (2016) (30)
- Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. (1991) (29)
- A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. (2001) (29)
- Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. (1998) (29)
- Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. (2001) (29)
- Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status (2013) (28)
- Weekly Carboplatin and Paclitaxel in Elderly Non–Small-Cell Lung Cancer Patients (≥65 Years of Age): A Phase II North Central Cancer Treatment Group Study (2003) (28)
- Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. (1998) (28)
- Consensus Proposal for 5-HT3 Antagonists in the Prevention of Acute Emesis Related to Highly Emetogenic Chemotherapy (1998) (28)
- Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: The SOFT, TEXT, and PERCHE trials (2003) (28)
- A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. (2007) (27)
- Abstract S1-06: Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit (2015) (27)
- Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance (2008) (27)
- Patient Age and Preoperative Breast MRI in Women With Breast Cancer: Biopsy and Surgical Implications (2011) (26)
- Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors (2016) (26)
- P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer (2007) (25)
- Changes to adjuvant systemic therapy in breast cancer: a decade in review. (2010) (25)
- EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial (2014) (25)
- Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results (2017) (25)
- Intrinsic Subtype and Therapeutic Response Among HER2‐Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial (2017) (25)
- Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies (2011) (25)
- Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer (2009) (25)
- A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21) (2007) (25)
- Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors (2015) (25)
- Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. (1995) (24)
- P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET) (2007) (24)
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (23)
- Optimizing adjuvant chemotherapy in early-stage breast cancer. (2005) (23)
- A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). (2012) (23)
- P118 ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 2-06/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer (BC) (2007) (23)
- Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 (2013) (22)
- Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. (2016) (22)
- N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC) (2005) (22)
- A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103) (2012) (22)
- Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. (2014) (22)
- Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study (2015) (22)
- Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. (2013) (22)
- Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). (2010) (22)
- Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer (2014) (22)
- Progress against solid tumors in danger: the metastatic breast cancer example. (2012) (21)
- North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. (2005) (21)
- Reply to E.A. Rakha et al. (2015) (21)
- Gemcitabine and targeted therapy in metastatic breast cancer. (2002) (21)
- New therapies in the treatment of breast cancer. (2006) (21)
- A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. (2012) (21)
- Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (20)
- Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. (2019) (20)
- Appraising adjuvant aromatase inhibitor therapy. (2006) (20)
- An Integrated Model of the Transcriptome of HER2-Positive Breast Cancer (2013) (20)
- RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer (2013) (20)
- Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol (2018) (20)
- A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932 (2005) (20)
- The balance between risks and benefits: Long-term use of aromatase inhibitors (2006) (20)
- Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways (2009) (20)
- Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. (2014) (20)
- High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance) (2018) (20)
- Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer (2015) (20)
- Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy: An NCCTG-97-24-51 Based Study (2009) (19)
- A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. (2006) (19)
- The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 (2015) (19)
- Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients (2020) (19)
- Impact of Library Preparation on Downstream Analysis and Interpretation of RNA-Seq Data: Comparison between Illumina PolyA and NuGEN Ovation Protocol (2013) (19)
- Breast cancer prevention trials (2000) (19)
- Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis (2005) (19)
- Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. (2004) (18)
- A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338 (2013) (18)
- North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. (2012) (18)
- Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. (1998) (18)
- Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. (2004) (18)
- Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma (1997) (18)
- Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform (2010) (18)
- N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy (2008) (18)
- Management of locally advanced breast cancer. (1997) (17)
- Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. (2021) (17)
- TAC--a new standard in adjuvant therapy for breast cancer? (2005) (17)
- The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies (2001) (17)
- In Newly Diagnosed Breast Cancer, Screening MRI of the Contralateral Breast Detects Mammographically Occult Cancer, Even in Elderly Women: The Mayo Clinic in Florida Experience (2010) (17)
- Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies. (2009) (17)
- Novel enhanced delivery taxanes: an update. (2007) (17)
- HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. (2004) (17)
- How well do standard prognostic criteria predict oncotype DX (ODX) scores (2007) (16)
- Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. (1991) (16)
- Issues and controversies in the treatment of HER2 positive metastatic breast cancer (2008) (16)
- Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial (2001) (16)
- BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. (2006) (16)
- Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT3 regimen and literature review (1999) (16)
- Immunoscoring breast cancer: TILs remember what they target. (2014) (16)
- A Risk-Benefit Assessment of Serotonin 5-HT3 Receptor Antagonists in Antineoplastic Therapy-Induced Emesis (1998) (16)
- Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. (2004) (16)
- P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET) (2007) (16)
- Paclitaxel and carboplatin for advanced breast cancer. (1996) (16)
- Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples (2013) (15)
- Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
- Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. (2012) (15)
- Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy (2004) (15)
- Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. (2006) (14)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (14)
- Safety of aromatase inhibitors in the adjuvant setting (2007) (14)
- Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC) (2008) (14)
- A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer (2007) (14)
- A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. (2013) (14)
- The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. (1994) (13)
- Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. (2008) (13)
- Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. (2016) (13)
- Dual HER2 blockade: preclinical and clinical data (2014) (13)
- Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG (2005) (13)
- The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. (2015) (13)
- Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. (2012) (13)
- Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide (1996) (13)
- Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients (2020) (13)
- Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer (2013) (12)
- Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis (2004) (12)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- HER2 testing and its predictive utility in anti-HER2 breast cancer therapy. (2015) (12)
- Serotonin antagonists in the management of cisplatin-induced emesis. (1991) (12)
- Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. (2014) (12)
- 5‐HT3 antiemetic therapy for patients with breast cancer (1999) (12)
- Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) (2015) (12)
- A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105). (2012) (11)
- Safety of aromatase inhibitors in the adjuvant setting (2007) (11)
- Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012) (2009) (11)
- Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). (2006) (11)
- Role of Gemcitabine in Breast Cancer Management: An Update. (2006) (11)
- Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. (2004) (11)
- High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically (1998) (11)
- 361PDINTERIM SAFETY AND EFFICACY OF PERTUZUMAB, TRASTUZUMAB AND VINORELBINE FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC). (2014) (11)
- Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. (2006) (11)
- Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. (2017) (11)
- Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. (2021) (11)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (11)
- Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE. (2017) (10)
- Abstract B7: A church-based, Spanish-language community education breast health program increases awareness and utilization of breast diagnostic services among Hispanics (2009) (10)
- Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer (2018) (10)
- Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. (2011) (10)
- N02C1: A phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC) (2008) (10)
- Recent advances in adjuvant therapy for breast cancer. (2003) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. (2009) (10)
- N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. (2013) (10)
- Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. (1996) (9)
- Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. (2011) (9)
- SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally advanced breast cancer (2016) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up (2016) (9)
- Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. (2017) (9)
- Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance). (2014) (9)
- Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy (2017) (9)
- Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). (2012) (9)
- MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. (2015) (9)
- Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT) (2005) (9)
- Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group ( NCCTG ) trials (2011) (8)
- Efficacy and safety of oral granisetron vs IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting (1997) (8)
- Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials. (2014) (8)
- Relationship between HER 2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM 4450 g : a randomized phase II study of patients with previously untreated HER 2-positive metastatic breast cancer (2014) (8)
- 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features. (2012) (8)
- Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. (2011) (8)
- Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer: A North Central Cancer Treatment Group Study (2010) (8)
- Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer (2021) (8)
- Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials. (2018) (8)
- Advances in the control of chemotherapy-induced emesis. (1992) (8)
- Adjuvant therapy approaches to breast cancer: Should taxanes be incorporated? (2003) (8)
- Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831. (2013) (8)
- A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study. (2004) (8)
- Biomarkers and Precision Medicine in Oncology Practice and Clinical Trials (2019) (7)
- Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (2021) (7)
- New developments in metastatic breast cancer: integrating recent data into clinical practice. (2013) (7)
- Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases (2020) (7)
- Metastatic bone disease in breast cancer: the patient's perspective. (2001) (7)
- Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line. (1994) (7)
- North Central Cancer Treatment Group--achievements and perspectives. (2008) (6)
- Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting. (1995) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer. (2010) (6)
- N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. (2010) (6)
- High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group (2004) (6)
- Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial. (2009) (6)
- Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer (2015) (6)
- The Globalization of Cooperative Groups. (2015) (6)
- Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). (2011) (6)
- Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. (2015) (6)
- Combinations of paclitaxel and etoposide in the treatment of lung cancer. (1996) (6)
- Paclitaxel plus nonanthracycline combinations in metastatic breast cancer. (1999) (6)
- How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer? (2013) (5)
- Cardiac issues related to trastuzumab. (2004) (5)
- Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC) (2010) (5)
- Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). (2014) (5)
- Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? (2011) (5)
- Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact. (2014) (5)
- Letrozole: present and future role in the treatment of breast cancer (2007) (5)
- Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. (2014) (5)
- N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen (2008) (5)
- Fine‐needle aspiration cytology in locally advanced breast adenocarcinoma: A case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction (1994) (5)
- Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. (1994) (5)
- Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity. (2011) (5)
- N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. (2018) (5)
- Breast cancer brain metastases: Molecular subtype, treatment and survival. (2016) (5)
- 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (2020) (5)
- NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC) (2007) (5)
- Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial (2016) (5)
- The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831. (2013) (5)
- Phase I study of panobinostat (LBH589) and letrozole in post-menopausal women with metastatic breast cancer. (2012) (5)
- Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization (2010) (5)
- Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study. (2013) (5)
- Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy (2012) (5)
- Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (2017) (5)
- Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. (2009) (5)
- Phase II trial of oral vinorelbine for treatment of metastatic breast cancer in women 65 years and older: N003A (2005) (4)
- Cisplatin and fluorouracil with or without sodium diethyldithiocarbamate rescue. (1988) (4)
- North Central Cancer Treatment Group N0531 (2005) (4)
- The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC). (2013) (4)
- Pre-operative breast magnetic resonance imaging (MRI) influences patient selection for partial breast irradiation. (2006) (4)
- Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome (2013) (4)
- The concordance between NCCTG's and NSABP's C-myc FISH assays (2008) (4)
- Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen (2000) (4)
- IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831 (2017) (4)
- Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study (2006) (4)
- Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC) (2008) (4)
- Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC) (2013) (4)
- Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials (2019) (4)
- Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52. (2013) (4)
- N0539 Phase II Trial of Fulvstrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial. (2009) (4)
- Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial. (2006) (4)
- Phase I Trial of Edatrexate in Advanced Breast and Other Cancers (2002) (4)
- EGF receptor/ErbB isoforms as serum biomarkers in breast and ovarian cancer (2002) (3)
- New treatment strategies in the management of breast cancer (2011) (3)
- miR-221-5p-Mediated Downregulation of JNK2 Aggravates Acute Lung Injury (2021) (3)
- Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance) (2021) (3)
- Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet) (2012) (3)
- Adjuvant anti-HER2 monoclonal antibody therapy – ready for breast cancer? (2001) (3)
- New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. (2011) (3)
- Utilization of gene expression profiling to identify markers of disease recurrence in node-negative breast cancer (2001) (3)
- Genes associated with serum estrone, estrone conjugates, and androstenedione concentrations in postmenopausal women with estrogen receptor-positive breast cancer. (2014) (3)
- Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy (2010) (3)
- Abstract P6-13-01: Local excision without radiation for ductal carcinoma in situ: 12-year results from the ECOG E5194 study (2015) (2)
- Perspectives from the American Society of Clinical Oncology 2014 Conference: breast cancer highlights. (2014) (2)
- Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831 (2008) (2)
- N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+ metastatic breast cancer. (2009) (2)
- Role of gemcitabine in breast cancer management: an update. (2006) (2)
- Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (2)
- Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. (2011) (2)
- Biomarker testing methods in breast, gastric, and lung cancers: A benchmarking survey of NCI cancer centers. (2013) (2)
- Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review (2022) (2)
- Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer. (2015) (2)
- Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic cancer research consortium trial RC0639. (2009) (2)
- Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. (2014) (2)
- High Dose Cisplatin: Modulation of Toxicity (1991) (2)
- Phase I trial of a 5-day infusion ofL-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies (2004) (2)
- Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. (2014) (2)
- Zoledronic acid (ZA) prevents aromatase inhibitor (Al)-associated bone loss in postmenopausal women with early breast cancer -36-month follow-up of the Z-FAST study (2008) (2)
- Increased expression of folate receptor-α (FRA) in triple-negative breast cancer: A potential therapeutic target. (2013) (2)
- Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer (2013) (2)
- Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort. (2020) (2)
- Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study (2020) (2)
- Managing high-risk breast cancer. (2007) (2)
- Lack of publication bias related to results from trastuzumab study (2008) (2)
- Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial. (2021) (2)
- Individualizing treatment to optimize survival outcomes in breast cancer. (2013) (2)
- Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1 (2021) (2)
- Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer. (2014) (2)
- Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways. (2009) (2)
- Management recommendations for adjuvant systemic breast cancer therapy. (2004) (2)
- 101P Significant Antitumor Activity in A Randomized Phase 2 Study Comparing 2 Schedules of Nktr-102 In Patients (Pts) with Metastatic Breast Cancer (Mbc) (2012) (2)
- Phase III adjuvant trial of concurrent epirubicin/taxane vs. sequential epirubicin/cyclophosphamide followed by taxane for node positive breast cancer. (2006) (2)
- Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). (2014) (2)
- Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (2015) (2)
- Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials (2022) (2)
- Adjuvant Chemotherapy: Controversies and the Role of Taxanes (2003) (2)
- Adjuvant trastuzumab for HER2-positive early breast cancer. (2010) (2)
- Mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging in the elderly (2008) (2)
- In newly diagnosed breast cancer, is a contralateral prophylactic mastectomy necessary following a negative MRI? (2009) (2)
- Exploratory Analysis of the Relationship Between Her2 Expression (BY QRT-PCR) and Efficacy with First-Line Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (HT) in a Randomized Phase 2 Study of Patients (PTS) with HER2-Positive MBC (2012) (2)
- New developments in metastatic breast cancer: general discussion. (2013) (2)
- Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC). (2013) (2)
- Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer (2022) (1)
- Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer. (2006) (1)
- Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007. (2008) (1)
- Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer. (2020) (1)
- Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study (2021) (1)
- Analysis of magnetic resonance imaging (MRI) in the detection of mammographically occult breast carcinoma (2007) (1)
- Highlights in breast cancer from the 2015 American Society of Clinical Oncology annual meeting. (2015) (1)
- 476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1 (2010) (1)
- Chemotherapy of metastatic testicular cancer: Current status and future prospects (1990) (1)
- Predictive Biomarkers and Personalized Medicine Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials , N 0234 / 336 / 436 / 437 (2011) (1)
- Evaluation of platinum-based chemotherapy, glutathione metabolic genes, and survival in advanced non small cell lung cancer: A NCCTG 97-24-51 based study. (2006) (1)
- Disease-Specific Therapeutic Targets in Breast Cancer Detection of Redundant Fusion Transcripts as Biomarkers or (2012) (1)
- Highlights in breast cancer from the 2014 American Society of Clinical Oncology® annual meeting. (2014) (1)
- Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer (2014) (1)
- Reply to P.G. Gavin et al. (2015) (1)
- Dual HER2 blockade: preclinical and clinical data (2014) (1)
- Management of Bone Metastases in Advanced Breast Cancer. (1999) (1)
- 53 Phase II study and pharmacokinetics of oral etoposide and intravenous paclitaxel in extensive stage small cell lung cancer: An NCCTG study (1997) (1)
- Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study. (2013) (1)
- Identification of risk factors in mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging (MRI) (2007) (1)
- Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC). (2012) (1)
- Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. (2021) (1)
- Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E. (2010) (1)
- Evaluation of axillary node dissection on measures of upper-extremity disability and overall quality of life after breast cancer surgery. (2010) (1)
- A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC) (2005) (1)
- Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG) (2007) (1)
- Abstract P3-10-03: Etirinotecan pegol target-specific pharmacodynamic biomarkers in circulating tumor cells from patients with metastatic breast cancer in the phase 3 BEACON study (2015) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. (2010) (1)
- Managing chemotherapy-induced nausea and vomiting (1996) (1)
- Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831. (2017) (1)
- Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors (2021) (1)
- Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831. (2009) (1)
- Adjuvant therapy trials of radiotherapy and systemic treatment for breast cancer (2002) (1)
- RESPONSE: Re: HER2 Testing in the Real World (2003) (1)
- Intraventricular (IVe) topotecan for women with neoplastic meningitis (NM) associated with "responsive" malignancies. (2012) (1)
- 5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry (2015) (1)
- Abstract PD5-06: Digital spatial mapping of the immune landscape of triple negative breast cancer reveals novel features of immune-tumor cell interaction (2020) (1)
- 170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial (2020) (1)
- Abstract 2005: Analysis of gene expression and copy number variation in breast tumors using both sequencing and hybridization-based platforms. (2013) (1)
- Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10. (2022) (1)
- Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer (2012) (1)
- Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results (2016) (0)
- Multicenter P hase I I T rial o f W eekly P aclitaxel i n W omen With M etastatic B reast C ancer (2001) (0)
- Predictive Biomarkers and Personalized Medicine Impact of c-MYC Protein Expression on Outcome of Patients withEarly-StageHER 2 þ BreastCancerTreatedwithAdjuvant Trastuzumab NCCTG ( Alliance ) N 9831 (2013) (0)
- N0937(Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC). (2013) (0)
- Abstract 3185: The eSNV-Detect: a computational system to identify expressed single nucleotide variants from tumor transcriptomes. (2013) (0)
- Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance) (2015) (0)
- In vitro cytotoxicity of cisplatin and carboplatin in human non small cell lung cancer lines (1991) (0)
- Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer (N1031, Alliance). (2012) (0)
- Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer." (2009) (0)
- Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs). (2022) (0)
- Letrozole in postmenopausal women after five years on tamoxifen (2004) (0)
- NCCTG N0338: effect of docetaxel and carboplatin on VEGF, PGE2, and immune cells in patients with stage II or III breast cancer. (2009) (0)
- Highlights in metastatic breast cancer from the 2012 American Society of Clinical Oncology Annual Meeting. (2012) (0)
- Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer (2010) (0)
- The eSNV-Detect workflow. (2013) (0)
- Abstract 1682: Correlation of immune co-stimulatory molecule OX40 and outcome in trastuzumab treated HER2-positive breast cancer patients in the NCCTG-N9831 (2017) (0)
- Molecular Profiling in Breast Cancer (2006) (0)
- Abstract LB-276: Fusion transcripts in breast cancer cell lines and tumors (2011) (0)
- Abstract P6-07-03: An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data (2015) (0)
- CASPER plots for 2 genes. (2013) (0)
- Phase I study of high-dose cisplatin, ifosfamide, and etoposide (1994) (0)
- Rapidly aternating radiotherapy and high-dose cisplatin in stage III non-small-cell lung cancer (1992) (0)
- Abstract P2-11-05: Effects of Intrinsic Subtypes and 21-gene Assay on the Early and Late Recurrence Risks in Patients with Early Stage HER2+ Breast Cancer: An Analysis of the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial (2023) (0)
- Abstract PS6-02: Spatially defined immune-related proteins and outcome in triple negative breast cancer in the FinXX trial and Mayo Clinic cohort (2021) (0)
- New biomarkers for intervention in breast cancer (2011) (0)
- Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
- Comparison of binary efficacy endpoints in 11 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials. (2009) (0)
- Abstract 4761: Characterization of individual foci of multifocal invasive lobular breast cancer using gene expression profiling (2015) (0)
- Abstract PS6-03: Prognostic value of clinical treatment score post-5 years (CTS5) and late relapse risk in hormone receptor-positive HER2-positive breast cancer in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) and NSABP B-31 (NRG) trials (2021) (0)
- Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437. (2009) (0)
- Prevention and Adjuvant Therapy in Breast Cancer (2014) (0)
- Abstract 5627: Functional tertiary lymphoid structure (TLS) and outcome in HER2-positive (HER2+) breast cancer in NCCTG N9831 (Alliance) (2022) (0)
- Update on metastatic breast cancer (1999) (0)
- Blood Type and the Risk of Gastric Disease (1994) (0)
- Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer. (2000) (0)
- An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data. (2014) (0)
- Representation of single nucleotide variant validation. (2013) (0)
- A Retrospective Review of Patients with Adenoid Cystic Breast Cancer Treated at Mayo Clinic. (2009) (0)
- Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the NCCTG N9831 (Alliance) Study (2019) (0)
- Role of SULT1A1 copy number in tamoxifen treated breast cancer: Findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89–30–52 (2008) (0)
- Adjuvant Therapy for Breast Cancer: Current Approaches and Strategies for a Better Future (2008) (0)
- Abstract 1004: Quantitative digital spatial profiling reveals novel prognostic intratumoral immune signatures in triple-negative breast cancer (2020) (0)
- Challenges in applying recent clinical trial data to the care of patients. (2010) (0)
- Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (0)
- Anti-cancer treatment - 12th International Congress. 4-7 February 2002, Paris, France. (2002) (0)
- Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer. (2016) (0)
- Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients withAdvancedBreastCancerafterTreatmentwith (2018) (0)
- Erratum to: Dual HER2 blockade: preclinical and clinical data (2014) (0)
- Erratum to: Dual HER2 blockade: preclinical and clinical data (2014) (0)
- How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer? (2013) (0)
- Adjuvant therapy in breast cancer (2012) (0)
- Metastatic Breast Cancer (2010) (0)
- Abstract B67: Collaboration between Volunteers in Medicine, serving the working uninsured, and Mayo Clinic, an academic medical center, addresses breast cancer outcome disparities and increases minority representation in cancer clinical trials (2009) (0)
- Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens (2004) (0)
- Does tamoxifen improve the outcome of patients who have undergone lumpectomy and radiation for ductal carcinoma in situ? (2000) (0)
- Abstract C114: Androstenedione levels in postmenopausal women with resected early-stage breast cancer are associated with SNPs in CYP11B1 and CYP11B2 identified by a genome-wide association study (GWAS). (2011) (0)
- Dr. Bryant and colleagues reply [7] (2006) (0)
- Clustering of genes uniquely expressed in HER2 tumors. (2013) (0)
- Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer (2018) (0)
- Comment on: HER2 testing in the real world. Authors' reply (2003) (0)
- A multidisciplinary approach to the management of breast cancer, Part 1 Prevention and diagnosis. Commentary (2007) (0)
- Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
- Endpoint comparison for osteoporosis assessment in cancer control studies (N02C1 and N03CC) (2008) (0)
- Other significant research and future directions (2006) (0)
- Schematic of analytical approach. (2013) (0)
- Abstract 4926: Modeling the transcriptome landscape of HER2+ breast cancer (2012) (0)
- Methods workflow for HER2 transcriptomic network. (2013) (0)
- Next-generation targeted agents in HER2-positive metastatic breast cancer. (2012) (0)
- Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study (2020) (0)
- Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD) (2017) (0)
- Abstract CT133: Results of phase I study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple negative breast cancer (2021) (0)
- Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials (2022) (0)
- Abstract 4908: Deep sequence analysis of the relationship between gene expression, CpG island methylation, and gene copy number in breast cancer cells (2011) (0)
- Abstract P4-01-17: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer (2023) (0)
- Reply to S. Mahesh (2012) (0)
- Impact of race pace on development of hyponatraemia in full- and half-marathoners (1970) (0)
- ISS3-1-2Age-related disparity in early prognosis of patients with triple-negative breast cancer: An analysis of SEER registries (2015) (0)
- P3-06-02: Identification of Redundant, Tumor Subtype Specific Fusion Transcripts in Primary Breast Tumors. (2011) (0)
- Abstract 4975: Next generation sequencing reveals a connection between KRAS mutation and the NFkB pathway in lung adenocarcinoma samples (2011) (0)
- National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer Reply (2015) (0)
- Current treatment options for metastatic breast cancer: what now? (2011) (0)
- N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer (2020) (0)
- Erratum: Changes to adjuvant systemic therapy in breast cancer: A decade in review (Clinical Breast Cancer (2010) 10:3 (196-208) DOI: 10.3816/CBC.2010.n. 027) (2010) (0)
- New treatment paradigms for optimizing survival in advanced and metastatic breast cancer. (2012) (0)
- Reply to J.M. Guinebretiere and L. Arnould et al (2009) (0)
- Identification and targeting of M-phase progression downstream of HER2 in trastuzumab-sensitive and -resistant breast cancer cell lines. (2014) (0)
- Increased Incidence of Loco-Regional Recurrences Among African American Women with Terminal Stage Breast Cancer (2007) (0)
- Whole Genome Profiling of Formalin-Fixed, Paraffin-Embedded Tissue Distinguishes HER2-Positive and -Negative Breast Tumors. (2009) (0)
- Reply to C. Shah et al. (2016) (0)
- How Do I Treat Patients with Advanced HER2-Positive Breast Cancer? (2013) (0)
- Pharmacologic reversion of epigenetic silencing of the PRKD1promoter blocks breast tumor cell invasion and metastasis (2013) (0)
- Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials. (2010) (0)
- Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance) (2022) (0)
- In reply [2] (2006) (0)
- Review: Routine follow-up tests do not improve survival and quality of life in women after treatment for early-stage breast cancer (2000) (0)
- “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy (2015) (0)
- A 55-YEAR-OLD WOMAN WITH CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (2005) (0)
- Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC) (2020) (0)
- Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (2019) (0)
- Quality of life (QoL) and content validity in objective tumor response. (2013) (0)
- HER-2 central confirmatory testing using ASCO/CAP guidelines for trastuzumab/lapatinib trial MCCR RC0639. (2016) (0)
- Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. (2023) (0)
- Screening for clonal hematopoiesis as a predictive marker for development of t-AML following adjuvant therapy for breast cancer (S0012) (2007) (0)
- Abstract B123: Analysis of the associations of FC gamma receptor polymorphisms (FCGR3A, FCGR2A, and FCGR2B) with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) trial N9831 (2013) (0)
- Breast cancer brain metastases: Comprehensive review of tumor extent, histology and treatment on survival. (2015) (0)
- Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. (2011) (0)
- The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 (2015) (0)
- Positive Breast Cancer − Beyond Trastuzumab : Small Molecule Tyrosine Kinase Inhibitors in HER-2 (2009) (0)
- P0154 Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: A population-based study from Surveillance, Epidemiology, and End Results (SEER) cancer registries (2015) (0)
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) (2023) (0)
- Reply to N. Magné et al (2009) (0)
- Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM) (2016) (0)
- Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial. (2020) (0)
- Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Practice-changing data in metastatic breast cancer. (2013) (0)
- A Practical Clinical Approach to Adjuvant Therapy in Breast Cancer—An Update (2009) (0)
- Tamoxifen added to lumpectomy and radiation therapy reduced breast cancer events in ductal carcinoma in situ (2000) (0)
- Highlights from the 3rd Breast–Gynecological International Cancer Conference 2011 (2011) (0)
- Genes regulating estradiol and estrone-conjugate levels in postmenopausal women with resected early-stage breast cancer detected by a genome-wide association study (GWAS). (2011) (0)
- JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines (2006) (0)
- 102P Phase 3 Study Of Nktr-102 Versus Treatment of Physician's Choice (Tpc) in Patients (Pts) with Locally Recurrent or Metastatic Breast Cancer (Mbc) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Atc) (2012) (0)
- Fluoxetine may reduce hot flashes in women with a history of breast cancer (2002) (0)
- Advances in combination chemotherapy in metastatic breast cancer (2005) (0)
- Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial (2014) (0)
This paper list is powered by the following services:
Other Resources About Edith A. Perez
What Schools Are Affiliated With Edith A. Perez?
Edith A. Perez is affiliated with the following schools:
- Indiana University
- Semmelweis University
- University of Puerto Rico
- University of Toronto
- New York University
- Kyoto University
- University of North Dakota
- Duke University
- Université libre de Bruxelles
- Washington University in St. Louis
- Indiana University Bloomington
- University of Washington
- University of Pittsburgh
- Rush University
